CRISPR Therapeutics (NASDAQ: CRSP)
$55.62
(-6.7%)
-$3.97
Price as of August 5, 2025, 3:58 p.m. ET
CRISPR Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CRISPR Therapeutics Company Info
CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations to treat and cure diseases.
News & Analysis
The Fool has written over 400 articles on CRISPR Therapeutics.
Featured Article
Up 50% in 3 Months, Is This Stock Still a Buy?
This biotech's innovative ways might eventually pay off.
Prosper Junior Bakiny | Aug 5, 2025
Featured Article
The 3 Things That Matter for CRISPR Therapeutics Now
As time marches on, the factors that could make or break this stock are becoming crystal clear.
James Brumley | Jul 29, 2025
3 Monster Stocks in the Making to Buy Right Now
Keith Speights, David Jagielski, and Prosper Junior Bakiny | Jul 21, 2025
2 Beaten-Down Stocks With Massive Upside Potential
Prosper Junior Bakiny | Jul 3, 2025
Top ETFs Tracking CRISPR Gene Editing
Keith Speights | Jun 18, 2025
These exchange-traded funds track companies in this biotech space.
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
Prosper Junior Bakiny | Jun 2, 2025
CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?
Cory Renauer | May 20, 2025
Prediction: This Beaten-Down Stock Could Double in The Next 5 Years
Prosper Junior Bakiny | May 18, 2025
Valuation
Podcast Episodes
"The Era of the Gene-Edited Human Is Here"
An investor's look.
Chris Hill | Sep 19, 2022
Breaking Down CRISPR Technology
What investors need to know.
Karl Thiel | Sep 28, 2021
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Todd Campbell | Nov 22, 2019
Did China’s “Designer Babies” Just Open Pandora’s Box?
What will this mean for healthcare and for the future of society?
Motley Fool Staff | Dec 21, 2018
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.